SCHEMBL30177455

SCHEMBL30177455

O=C(CNC(=O)OCc1ccccc1)NNC(=O)c1cc2c(Br)cccc2n1CC(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.40
LMNA P02545 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
F10 P00742 4/20 0.39
TPSAB1 Q15661 2/20 0.39
TPSD1 Q9BZJ3 2/20 0.39
TPSG1 Q9NRR2 2/20 0.39
PRSS1 P07477 1/20 0.39
ALDH1A1 P00352 2/20 0.38
GLA P06280 1/20 0.36
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
MAPK1 P28482 1/20 0.36
F2 P00734 1/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30177357 0.83 PLAU (0.37) HTTLMNANPSR1F10TPSAB1
SCHEMBL30177352 0.83 PLAU (0.37) HTTLMNANPSR1F10TPSAB1
SCHEMBL24036359 0.76 F10 (0.43) F10F2
SCHEMBL26734016 0.74 SMN1; SMN2 (0.37) LMNASMN1; SMN2
SCHEMBL30177510 0.74 ALDH1A1 (0.37) LMNAALDH1A1
SCHEMBL24035596 0.73 CCR2 (0.48) F10GLAKDM4E
SCHEMBL30177453 0.73 CYP2D6 (0.43)
SCHEMBL30177493 0.73 TNKS (0.34)
SCHEMBL24035205 0.72 LDHA (0.40) HTTLMNAF10SMN1; SMN2
SCHEMBL24036358 0.70 F10 (0.45) LMNANPSR1F10ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043436-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2024-02-08 US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 US disclosed
EP-4149459-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2023-03-22 EP disclosed
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS HTT 2787/4885LMNA 2728/4885NPSR1 4742/4885
US-11807644-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS HTT 2787/4885LMNA 2728/4885NPSR1 4742/4885
US-20240043436-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS HTT 2787/4885LMNA 2728/4885NPSR1 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.